[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"mesenchymal-stem-cells\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:mesenchymal-stem-cells":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,44,71,94,121,149],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":4},"100637502","phase-1-exploratory-study-on-the-efficacy-and-safety-of-nebulized-huc-msc-derived-exosomes-for-non-acute-cip-100637502",false,"NCT07599111","Exploratory Study on the Efficacy and Safety of Nebulized hUC-MSC-Derived Exosomes for Non-Acute CIP","Exploratory Study on the Efficacy and Safety of Nebulized Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in the Treatment of Non-Acute Immune Checkpoint Inhibitor-Related Pneumonitis","Inclusion Criteria:\n\n* Informed consent: Signed written informed consent.\n* Age and diagnosis: Aged 18-75 years with histologically confirmed malignant tumor.\n* Treatment history: Received at least one cycle of immune checkpoint inhibitor therapy and developed immune checkpoint inhibitor-related pneumonitis.\n* Confirmed Grade 3-4 immune checkpoint inhibitor-related pneumonitis (CIP) by clinical evaluation (diagnosis and grading in accordance with the NCCN Guidelines for Management of Immunotherapy-Related Toxicities Version 1.2025), having received standard glucocorticoid therapy for ≥4 weeks, with glucocorticoids either discontinued or tapered to a prednisone-equivalent dose of \\\u003C20 mg\u002Fday.\n* Recent HRCT imaging: Persistent residual CIP-related lesions in both lungs, including ground-glass opacity, consolidation, reticular opacity, traction bronchiectasis, and\u002For honeycombing, involving a large extent of the lung fields; no significant resolution or improvement of these residual lesions on repeated HRCT within the past 4 weeks.\n* General condition: ECOG PS score 0-1, with stable control of the primary tumor for ≥6 months.\n* Contraception: Fertile subjects agree to use effective contraception during the study period and for 360 days after the last dose.\n\nExclusion Criteria:\n\n* Concomitant medication: Current use of antifibrotic agents such as pirfenidone and nintedanib.\n* Operational limitation: Inability to cooperate with pulmonary function testing or nebulized inhalation.\n* History of other pulmonary diseases: Presence of unresolved interstitial lung disease or pulmonary fibrosis induced by targeted therapy, radiotherapy, or other causes.\n* Severe comorbidities: Including severe cardiac, hepatic, or renal insufficiency, or severe hematological abnormalities.\n* Specific medical history: Severe neuromuscular disease, history of organ transplantation, active epilepsy, primary or severe acquired\u002Fsecondary immunodeficiency.\n* Other factors: Severe allergic constitution, psychiatric disorders, use of other investigational products within 28 days, or any other condition deemed inappropriate by the investigator.","ALL","18 Years","75 Years",{"count":20,"type":21},40,"ESTIMATED","INTERVENTIONAL",[24,25],"PHASE1","PHASE2","Study Objectives The primary objective of Phase II is to evaluate the percentage of lesion resolution on high-resolution computed tomography (HRCT) as assessed by independent blinded reviewers. Secondary objectives include evaluating effects on pulmonary function, exercise capacity, dyspnea, quality of life, and oxygenation, as well as comprehensively assessing safety and tolerability. Phase I focuses on determining safety, dose-limiting toxicities (DLT), and recommended Phase II dose.\n\nStudy Population\n\nThe target population is patients with non-acute CIP aged 18-75 years with histologically confirmed malignancy. Key inclusion criteria include:\n\nAt least one cycle of immune checkpoint inhibitor (ICI) therapy and development of Grade 3-4 CIP per NCCN Guidelines V1.2025 Standard glucocorticoid treatment for ≥4 weeks, with current dose \\\u003C20 mg\u002Fday prednisone equivalent or discontinued Persistent residual CIP lesions on HRCT without significant improvement in the past 4 weeks ECOG PS 0-1 and stable primary tumor for ≥6 months Effective contraception during the study and for 360 days after last dosing\n\nKey exclusion criteria include:\n\nConcomitant use of pirfenidone, nintedanib, or other antifibrotic agents Inability to perform pulmonary function tests or tolerate nebulization Unresolved interstitial lung disease from radiotherapy or targeted therapy Severe cardiac, hepatic, renal, or hematological dysfunction Organ transplantation, severe immunodeficiency, active epilepsy, or severe allergic status Other investigational drug use within 28 days Study Design and Sample Size Phase I: 9-18 subjects, open-label, dose-escalation design to evaluate DLT and safety Phase II: 40 subjects, randomized, double-blind, placebo-controlled design Study Endpoints Phase I Primary Endpoints Incidence of DLT Incidence of adverse events (AE) and serious adverse events (SAE) Phase II Primary Endpoint Percentage of HRCT lesion resolution at Weeks 4, 12, and 24, assessed by independent blinded reviewers Secondary Endpoints Pulmonary function: FVC%, TLC, RV, FRC, DLCO Functional and symptomatic measures: 6MWD, mMRC dyspnea score, SGRQ, LCQ Oxygenation: PaO₂, A-aDO₂, oxygenation index Exploratory Endpoints Dynamic changes in serum biomarkers: KL-6, cytokines (IL-1β, IL-6, IL-10), immune cell subsets (Tregs, Th1\u002FTh17) Safety Assessments Monitoring of AEs\u002FSAEs graded by CTCAE v5.0 and causality assessment Physical examination, vital signs, SpO₂, 12-lead ECG Laboratory tests: CBC, biochemistry, coagulation, urinalysis, CRP, ESR Study Termination Rules Overall Study Termination Successful completion after all 40 subjects finish 24-week follow-up and database lock Occurrence of unexpected serious or unacceptable safety risks Demonstration of overwhelming efficacy or futility Sponsor termination due to slow enrollment, funding, or major protocol deviations Regulatory or ethics committee requirements Individual Subject Discontinuation Development of DLT or severe hypersensitivity Rapid CIP progression (e.g., \\>50% radiological worsening) Tumor progression or clinical deterioration Withdrawal of informed consent Poor compliance unresponsive to intervention Loss to follow-up or death Investigator judgment of inappropriateness for continued participation Study Timeline Preparation and initiation: January 2026 - May 2026 Phase I\u002FII enrollment: June 2026 - May 2027 Treatment and follow-up (overlapping with enrollment): through June 2028 Database lock and statistical analysis: July 2028 - August 2028 Study closeout: August 2028 - December 2028",[28,29,30,31],"Pneumonitis, Interstitial","Immune Checkpoint Inhibitors (ICIs)","Mesenchymal Stem Cells","Exosomes","NOT_YET_RECRUITING","2026-05-13",{"date":35,"type":36},"2026-05-20","ACTUAL",{"date":38,"type":21},"2026-04",{"date":40,"type":21},"2028-10",{"name":42,"class":43},"Zhou Chengzhi","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":57,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100446599","phase-1-autologous-mesenchymal-stromal-cells-and-islet-co-transplantation-in-tp-iat-100446599","NCT05095532","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation in TP-IAT","Autologous Mesenchymal Stromal Cells and Islet Co-transplantation to Enhance Islet Survival and Function in Chronic Pancreatitis Patients Undergo Total Pancreatectomy and Islet Autotransplantation","Inclusion Criteria:\n\n* Diagnosis of CP and scheduled for TP-IAT;\n* ≥18 years old;\n* Diabetes with HbA1c \\\u003C12%.\n\nExclusion Criteria:\n\n* Patients who are under immunosuppression;\n* Pregnant and breastfeeding women.\n* Patients who have liver damage based on ALT, AST, and total bilirubin levels (\\>3 times normal levels);",{"count":52,"type":21},42,[24],"This is a clinical trial for chronic pancreatitis (CP) patients undergoing total pancreatectomy with islet autotransplantation (TP-IAT). Participants will be randomized to either bone marrow-derived mesenchymal stem cells (MSCs) or control with the standard of care. Participants will be followed for one-year post-transplant.",[56,30],"Chronic Pancreatitis",[58,59],"Total Pancreatectomy","TP-IAT","RECRUITING","2026-04-13",{"date":63,"type":36},"2026-04-16",{"date":65,"type":36},"2021-12-01",{"date":67,"type":21},"2027-06-30",{"name":69,"class":43},"Medical University of South Carolina",1,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":77,"eligibilityCriteria":78,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":70},"100632849","phase-1-study-of-umbilical-cord-mesenchymal-stem-cell-derived-exosomes-in-vitiligo-100632849","NCT07519031","Study of Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes in Vitiligo","A Single-Center, Randomized, Controlled Trial of Human Umbilical Cord Mesenchymal Stem Cell-Derived Exosomes for the Treatment of Vitiligo","hUMSCs-Exo-VIT","Inclusion Criteria:\n\n* Clinically diagnosed non-segmental vitiligo\n* Progressive vitiligo: new lesions or enlargement of existing lesions within the past 3 months (VIDA score ≥ 3); Stable vitiligo: no new lesions or enlargement of existing lesions within the past 1 year (VIDA score = 0)\n* Total body surface area (BSA) of vitiligo lesions between 1% and 30%\n* Age 18 to 65 years, male or female\n* Willing to participate and provide written informed consent\n\nExclusion Criteria:\n\n* Pregnancy or breastfeeding\n* Known allergy to mesenchymal stem cells or exosome components\n* Severe cardiac, hepatic, or renal dysfunction, or severe immunocompromised status\n* For progressive vitiligo: use of systemic immunosuppressants, corticosteroids, phototherapy, or photochemotherapy within the past 3 months\n* For stable vitiligo: use of phototherapy, topical immunosuppressants, or corticosteroids within the past 1 month\n* Concurrent autoimmune diseases (e.g., systemic lupus erythematosus, rheumatoid arthritis, psoriasis) or severe infectious diseases\n* History of malignancy or hematologic disorders\n* History of psychiatric disorders or inability to comply with study procedures\n* Any other condition that, in the investigator's judgment, may increase the risk to the participant or interfere with the conduct of the trial","65 Years",{"count":81,"type":21},96,[24,25],"This study evaluates whether exosomes derived from human umbilical cord mesenchymal stem cells (hUMSCs-Exo) are safe and effective for treating vitiligo in adults.\n\nVitiligo is a skin condition that causes white patches due to loss of pigment-producing cells. Current treatments have limitations, especially for patients with active disease who require oral steroids with significant side effects.\n\nThis study is a single-center, randomized, controlled trial enrolling 96 adults aged 18 to 65 years with non-segmental vitiligo. Participants are divided into two groups based on disease activity: progressive vitiligo (new patches appearing or existing patches expanding in the past 3 months) and stable vitiligo (no changes in the past year).\n\nFor progressive vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by intravenous infusion every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: oral prednisone (a standard steroid treatment) plus tacrolimus ointment and narrowband UVB light therapy\n\nFor stable vitiligo, participants are randomly assigned to either:\n\nExperimental group: hUMSCs-Exo given by local injection into the white patches every 2 weeks for 5 sessions, plus tacrolimus ointment and narrowband UVB light therapy, or Control group: tacrolimus ointment plus narrowband UVB light therapy alone The treatment period lasts 12 weeks, with follow-up visits continuing to 24 weeks. The main outcome measures include improvement in skin repigmentation measured by the Vitiligo Area Scoring Index (VASI), changes in quality of life, and safety monitoring throughout the study.\n\nThis study aims to establish a standardized approach for using hUMSCs-Exo in vitiligo treatment and to explore how exosomes may work by reducing oxidative stress and regulating immune responses.",[85,30,31],"Vitiligo","2026-04-01",{"date":88,"type":36},"2026-04-09",{"date":38,"type":21},{"date":91,"type":21},"2028-03",{"name":93,"class":43},"Xijing Hospital",{"id":95,"slug":96,"hasResults":11,"nctId":97,"briefTitle":98,"officialTitle":99,"acronym":100,"eligibilityCriteria":101,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":102,"targetDuration":4,"studyType":22,"phases":104,"briefSummary":105,"conditions":106,"keywords":108,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":112,"lastUpdatePostDateStruct":113,"startDateStruct":115,"completionDateStruct":117,"leadSponsor":119,"locationsCount":70},"100389853","phase-1-treatment-with-human-umbilical-cord-derived-mesenchymal-stromal-cells-in-systemic-sclerosis-100389853","NCT04356287","Treatment With Human Umbilical Cord-derived Mesenchymal Stromal Cells in Systemic Sclerosis","Phase I\u002FII Randomized Controlled Trial of Umbilical Cord-derived mesenChymAl stRomal cElls in Systemic Sclerosis","CARE-SSc","Inclusion Criteria:\n\n1. SSc according to American College of Rheumatology\u002FEuropean League Against Rheumatism (ACR\u002FEULAR) 2103 classification criteria for systemic sclerosis\n2. Severe disease defined as:\n\n   i) disease duration of 2 years or less with an mRss of \\> 20 and (ESR \\> 25 mm and\u002For hemoglobin \\\u003C 11 g\u002FdL, not explained by other causes than SSc), or ii) mRss \\>15 without any restriction as to disease duration plus at least one major organ involvement as defined by: a) respiratory involvement consisting of lung diffusion capacity for carbon monoxide (DLCO) and\u002For forced vital capacity (FVC) \\\u003C 80% predicted and evidence of interstitial lung disease (chest X-ray and\u002For high resolution computed tomography (HRCT) scan); b) renal involvement consisting of past renal crisis and\u002For stage 2 or 3 chronic kidney disease (glomerular filtration rate between 30-89 mL\u002Fmin) not explained by other causes than SSc; c) cardiac involvement consisting of reversible congestive heart failure, atrial or ventricular rhythm disturbances such as recurrent episodes of atrial fibrillation or flutter, recurrent atrial paroxysmal tachycardia, conduction abnormalities (2nd or 3rd degree atrioventricular block), and\u002For mild to moderate pericardial effusion. All causes of organ involvement should be attributed to SSc.\n3. Inadequate response (determined by patient and physician judgement) or adverse events necessitating discontinuation of standard therapy (usually consisting of methotrexate 25 mg subcutaneous (or as tolerated) per week and\u002For mycophenolate mofetil 2-3 gm\u002Fd (or as tolerated) for at least 3 months\n4. Ineligibility or unwillingness to undergo autologous hematopoietic stem cell transplant\n\nExclusion Criteria:\n\n1. Age \\\u003C 18 years\n2. Pregnancy or unwillingness to use adequate contraception\n3. Life-threatening end-organ damage defined as:\n\n   * FVC \\\u003C 45% and\u002For DLCO (corrected for hemoglobin) \\\u003C 30% predicted;\n   * Left ventricular ejection fraction \\\u003C 40% by cardiac echocardiography;\n   * Pulmonary hypertension with baseline resting systolic pulmonary arterial pressures \\> 50 mmHg by cardiac echocardiography, or mean pulmonary artery pressure \\> 25 mmHg (and pulmonary wedge pressure \\\u003C 15 mmHg) on right heart catheterization;\n   * stage 4 or more chronic kidney disease (glomerular filtration rate \\\u003C 30 ml\u002Fmin)\n4. Liver failure defined as an abnormal transaminase level (aspartate aminotransferase (ASAT), alanine aminotransaminase (ALAT) \\> 3 normal) unless related to activity of the disease\n5. Concurrent neoplasms or myelodysplasia\n6. Uncontrolled hypertension\n7. Uncontrolled acute or chronic infection (HIV, HTLV-1\u002F2 (Human T-lymphotropic virus), hepatitis B surface Ag positive, hepatitis C positive) or high risk thereof\n8. Significant malnutrition with BMI \\\u003C 18 kg\u002Fm2\n9. Severe concomitant psychiatric disorder\n10. Bone marrow insufficiency defined as neutropenia \\\u003C 0.5 x 109 cell\u002FL, thrombocytopenia \\\u003C 30 x 109 cell\u002FL, anemia \\\u003C 8g\u002FdL, CD4+ T lymphopenia \\\u003C 200 x 106 cell\u002FL due to other diseases than SSc (CD4 - cluster of differentiation 4)\n11. History of poor compliance\n12. Concurrent enrolment in any other protocol using an investigational drug\n13. Inability to provide informed consent",{"count":103,"type":21},18,[24,25],"The purpose of this study is to test the safety and efficacy of Umbilical Cord-derived Mesenchymal Stromal Cells (UCMSC) for the treatment of Systemic Sclerosis (SSc).",[107,30],"Sclerosis, Systemic",[109,110,111],"Systemic Sclerosis","Umbilical cord-derived mesenchymal stromal cells","Scleroderma, Systemic","2026-01-30",{"date":114,"type":36},"2026-02-03",{"date":116,"type":36},"2023-01-05",{"date":118,"type":21},"2027-12",{"name":120,"class":43},"Marie Hudson, MD",{"id":122,"slug":123,"hasResults":11,"nctId":124,"briefTitle":125,"officialTitle":126,"acronym":4,"eligibilityCriteria":127,"healthyVolunteers":11,"sex":128,"minAge":129,"maxAge":130,"enrollmentInfo":131,"targetDuration":4,"studyType":22,"phases":133,"briefSummary":134,"conditions":135,"keywords":137,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":140,"lastUpdatePostDateStruct":141,"startDateStruct":143,"completionDateStruct":145,"leadSponsor":147,"locationsCount":70},"100563023","phase-1-huc-msc-for-treatment-of-high-risk-hpv-infection-100563023","NCT06610773","HUC-MSC for Treatment of High-risk HPV Infection","Effectiveness and Safety of Human Umbilical Cord Mesenchymal Stem Cells for the Treatment of HPV High-risk Infection","Inclusion Criteria:\n\n1. Women aged 25-60 with a sexual history of more than 2 years;\n2. Confirmed HPV infection by HPV-24 test;Patients diagnosed with high-risk human papillomavirus (HR-HPV) persistent infection; (note: the HR HPV: HPV 16\u002F18\u002F31\u002F33\u002F35\u002F39\u002F45\u002F51\u002F52\u002F53\u002F56\u002F58\u002F59\u002F66\u002F68; 15 types)\n3. The subjects were not participating in other clinical trials at the same time, and had no other anti-HPV drugs or intervention therapy recently;\n4. If the pregnancy test is negative and the subjects have fertility potential, they agree to use effective contraception during the study period and within 6 months of completion or termination of the study;\n5. Voluntarily participate in and agree to cooperate in accordance with the requirements of the program, and sign the informed consent.\n\nExclusion Criteria:\n\n1. Women who are preparing for pregnancy, pregnancy or breastfeeding;\n2. Pathological diagnosis of high-grade squamous intraepithelial lesion (HSIL) or cervical cancer;\n3. Previous HPV vaccinations;\n4. A history of severe drug allergies, or allergies to stem cell products or other biologics;\n5. Previous cervical site physical therapy or related surgical history;\n6. Patients with severe immune dysfunction (such as AIDS, systemic lupus erythematosus and other immune system diseases or history of organ transplantation, malignant tumor chemotherapy history), serious cardiovascular, liver, kidney, nervous, hematopoietic system diseases or malignant tumors, or mental diseases;\n7. Recent use of other antiviral drugs, immunosuppressants, immunomodulators or steroid hormones that affect the immune system;\n8. Patients with acute genital tract inflammation or pelvic inflammation;\n9. Those who have participated in or are participating in clinical trials of other drugs within three months;\n10. Other conditions considered inappropriate by the investigator for inclusion in this clinical trial.","FEMALE","25 Years","60 Years",{"count":132,"type":21},60,[24,25],"To evaluate the safety and initial effectiveness of human umbilical cord mesenchymal stem cells in HPV clearance.",[136,30],"Human Papillomavirus Viruses",[138,139],"HPV","hUC-MSC","2024-09-22",{"date":142,"type":36},"2024-09-24",{"date":144,"type":36},"2024-03-01",{"date":146,"type":21},"2026-09-10",{"name":148,"class":43},"Shanghai East Hospital",{"id":150,"slug":151,"hasResults":11,"nctId":152,"briefTitle":153,"officialTitle":4,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":11,"sex":16,"minAge":155,"maxAge":156,"enrollmentInfo":4,"targetDuration":4,"studyType":157,"phases":4,"briefSummary":158,"conditions":159,"keywords":160,"overallStatus":164,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":168,"locationsCount":4},"100155920","cartilage-tissue-engineering-100155920","NCT01301664","Cartilage Tissue Engineering","Inclusion Criteria:\n\n* 30-70 years old\n\nExclusion Criteria:\n\n* more than 70 years old","30 Years","70 Years","EXPANDED_ACCESS","In this study, the investigators explored the hypothesis that osteoarthritic cartilage fragments can promote chondrogenesis of MSCs. Non-wearing parts of cartilage tissues were harvested from one osteoarthritic patient during the total knee arthroplasty surgery. Cartilage fragments and MSCs were wrapped into fibrin glue; and the constructs were implanted subcutaneously into nude mice.\n\nMoreover, the investigators will collect the discard cartilage to develop an acellular cartilage ECM-derived scaffold in the joint replacement surgery. In addition, the investigators will harvest the redundant bone marrow from drilling or useless synovium during the surgery to separate the mesenchymal stem cells. Furthermore, these mesenchymal stem cells will be transfected with hTERT for rejuvenation and then will be labeled with fluorescent dye PKH26 for application of animal study. To sum up, the investigators plan to use human, natural, and discard materials from the joint replacement surgery to develop appropriate allograft for cartilage repair and hope that one day this ideal would be apply in clinical.",[30],[161,162,163],"The bone marrow-derived mesenchymal stem cells (BMMSCs) were obtained from redundant bone marrow from drilling during the joint replacement surgery.","The synovial-derived mesenchymal stem cells (SMSCs) were isolated from synovial membranes in the joint replacement surgery.","Cartilage slices were obtained from discard cartilage in the joint replacement surgery.","AVAILABLE","2013-03-06",{"date":167,"type":21},"2013-03-07",{"name":169,"class":43},"Chin-Hung Chang"]